Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04115748 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy
A Phase 3 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 67
- Enrollment target
NCT04115748 is a Phase 3 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 67 participants.
The verdict
NCT04115748, a Phase 3 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 67 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effect of filgotinib compared to placebo as assessed by the American College of Rheumatology 20% improvement (ACR20) response in participants with active psoriatic arthritis who are naive to biologic disease-modifying anti-rheumatic drug (DMARD) therapy. The study consists of two parts, the Main Study and the Long Term Extension (LTE).
Interventions
- DRUG Adalimumab
- DRUG Filgotinib
- DRUG Placebo to match filgotinib
- DRUG Placebo to match adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2019-12-03 |
| Est. Completion | 2021-05-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04115748
The ClinicalTrials.gov registry entry for NCT04115748 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Adalimumab is the first listed.
NCT04115748 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04115748 about?
NCT04115748 is a clinical study titled "Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy". The primary objective of this study is to evaluate the effect of filgotinib compared to placebo as assessed by the American College of Rheumatology 20% improvement (ACR20) response in participants with active psoriatic arthritis who are naive to biologic disease-modifying anti-rheumatic drug (DMARD)...
What is the current status of trial NCT04115748?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 67 participants. The study started on 2019-12-03. Estimated completion is 2021-05-11.
What interventions are being tested in trial NCT04115748?
The interventions under investigation include: Adalimumab (DRUG), Filgotinib (DRUG), Placebo to match filgotinib (DRUG), Placebo to match adalimumab (DRUG).
Who is sponsoring clinical trial NCT04115748?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.